99.99+% consensus accuracy achieved across entire AmpliSeq™ portfolio

Life Technologies is proud to announce another major advancement in the performance trajectory of the Ion AmpliSeq Technology. The new Torrent Suite Software v3.0 now consistently delivers 99.99+% consensus accuracy for both short and long homopolymer regions, and increases the frequency of correctly called insertions, deletions and homopolymer sequences by two-fold.

Read length on the Ion PGM™ also continues its unprecedented scalability with today's launch of the 400 base sequencing kits, which will provide a broader range of applications, such as bacterial identification, metagenomic analysis, Human Leukocyte Antigen sequencing, and better de novo assemblies.

"Ion's new long read kits combined with accuracy increases from Torrent Suite v3.0 have enabled us to significantly improve the performance of our bacterial and metagenomic sequencing as well as microbial genome assemblies," said Professor Dag Harmsen of the University of Muenster,Germany — a researcher at the epicenter of last year's pathogenic E coli outbreak. "The rapid generation of long accurate reads by the Ion PGM Sequencer will truly enable the new science of prospective genomic epidemiology."

AmpliSeq™ Technology Transforms Research
Six months after its introduction to the market, Ion AmpliSeq Technology has significantly transformed the way hypothesis-driven research is conducted. More than 700 customers have completed over 2,500 gene panel designs and high throughput laboratories have achieved annual run rates of over 1,000 runs per Ion PGM System.  

A new Ion AmpliSeq Sample ID Panel reveals sample misidentification to increase confidence during data analysis and reporting. Ion Reporter Software now incorporates oncology and inherited disease trio research workflows. These advances improve the sensitivity and utility of all existing Ion AmpliSeq Panels, as well the soon to be launched Ion AmpliSeq Cancer Panel v2.  This new, ready-to-use panel offers additional oncogene content and approaches 100% coverage uniformity, further widening the performance gap relative to competing target enrichment products.

"The Ion AmpliSeq Technology has demonstrated a remarkable improvement in performance, specifically in exceptional coverage uniformity and additional mutational coverage, allowing for better overall economics and making causative variant identification much simpler," said William Strauss, Principal Research Scientist at Cynvenio Biosystems.

Ion semiconductor sequencing delivers both long reads and high throughput. In contrast, light-based sequencing technologies typically provide either short reads with high throughput, or longer reads with moderate throughput. The new Ion PGM Sequencing Kits include a long-read sequencing enzyme supporting two long read runs per day - versus days or weeks for light based sequencing systems. A 300-base template preparation kit is shipping, with a 400-base template preparation kit available in the fourth quarter of 2012.  Long read datasets including a 2 Gb run with 400 base reads are posted on the Ion Community

"We believe semiconductor sequencing is replacing light-based sequencing applications in the same way as digital photography put film out of business," said Dr. Jonathan Rothberg, CEO and founder of Ion Torrent.  "Ion AmpliSeq Technology is a perfect example of a tool that can help transform the way research is performed."

Diagnostic Road-Map
The rapid performance advancement of the Ion PGM™ Sequencer, including read-length, accuracy and throughput, position Life Technologies to "lock down" robust kits and protocols to prepare for 510(k) clearance with the U.S. Food and Drug Administration. The upgraded Ion AmpliSeq and Ion Reporter whole product solution also allows accurate and easy probing of disease-relevant genes, enabling useful advancements in research.

All above mentioned products are For Research Use Only. Not for use in diagnostic procedures.